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MiR-214 has been shown to inhibit cell growth, migration and invasion. Here we demonstrate that
ectopic expression of miR-214 reduces cell survival, induces apoptosis and enhances sensitivity to
cisplatin through directly inhibiting Bcl2l2 expression in cervical cancer HeLa and C-33A cells. Fur-
ther analysis reveals that apoptosis induced by miR-214 is correlated with increased expression of
Bax, caspase-9, caspase-8 and caspase-3. Moreover, we show that miR-214 is regulated by DNAmeth-
ylation and histone deacetylation. Taken together, these data suggest that miR-214 might be a can-
didate target for the development of novel therapeutic strategies to treat cervical cancer.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Cervical cancer is a highly prevalent cancer that affects women
across the world. Most women with early lesions are cured with
surgery or radiation alone. However, in patients with metastatic
diseases or those with more advanced lesions who are at signiﬁ-
cant risk of recurrence, chemotherapy is the only option. The stan-
dard regimen in this setting has been systemic cisplatin, but the
response rate is very low, mainly because the cancer cells fre-
quently develop resistance to chemotherapy agents. The cellular
mechanisms of drug resistance include over-expression of p-glyco-
proteins that eject anticancer drugs from cells, acquired mutations
in drug target cells and defects in cellular apoptosis pathways [1].
Recent reports have shown that microRNAs (miRNAs), which are
critical for many important processes such as development, differ-
entiation and even carcinogenesis, can regulate the chemosensitiv-
ity of tumor cells [2]. MiRNAs are approximately 22 nt in length
and regulate gene expression by binding to the 30untranslated re-gions (UTRs) of mRNAs, leading to mRNA degradation or repression
of translation. It has been reported that miR-122 sensitizes HCC
cancer cells to adriamycin and vincristine by modulating the
expression of MDR and inducing cell cycle arrest [3]. Over-expres-
sion of miR-15b and miR-16 sensitizes human gastric cancer cells
to VCR-induced apoptosis by reducing the levels of Bcl-2 [4]. How-
ever, the exact mechanisms underlying drug resistance in cervical
cancer cells have not been completely characterized. Therefore,
clarifying the mechanisms underlying cancer cell drug resistance
in detail and improving chemosensitivity should improve the sur-
vival rate in cervical cancer patients.
Our previous studies have demonstrated that miR-214 is fre-
quently down-regulated in cervical cancer tissues and that ecto-
pic expression of miR-214 can inhibit cellular proliferation,
growth, migration and invasion in the HeLa cervical cancer cell
line [5–7]. Here, we showed that miR-214 signiﬁcantly reduced
cell survival and rendered cell sensitivity to cisplatin through
inhibiting the anti-apoptotic protein Bcl2l2 using the stable cell
lines HeLa/miR-214 expressing high level of miR-214 and HeLa/
Neg-Ctrl as negative control cell line (established in our previous
work [6]) and another cervical cancer C-33A cell line. Further-
more, we found that miR-214 can induce apoptosis and enhance
the expression of Bax, caspase-9, caspase-3 and caspase-8, indi-
cating that miR-214 induced cell apoptosis partly though alter-
ing the ratio of Bax/Bcl2l2 and inducing the intrinsic apoptosis
pathway.
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2.1. Human tissue specimens and cell culture
Eleven paired human cervical cancer tissues and adjacent nor-
mal tissues were obtained from the Tumor Bank Facility of Tianjin
Medical University Cancer Institute and Hospital and National
Foundation of Cancer Research. Histologically, all the biopsies be-
longed to squamous cell carcinoma. The collection of human tissue
samples was approved and supervised by the Ethics Committee of
Tianjin medical university. Cervical cancer HeLa and C-33A cell
lines were obtained from the ATCC. HeLa/miR-214 cells and
HeLa/Neg-Ctrl cells were established and maintained in our labora-
tory [6]. These cells were grown in RPMI 1640 medium supple-
mented with 10% fetal bovine serum (FBS), 100 units/ml
penicillin and 100 mg/ml streptomycin. All transfections were per-
formed using LipofectAmine 2000 reagent (Invitrogen, Carlsbad,
CA, USA) according to the manufacturer’s recommendations.
2.2. Cell survival and cytotoxicity assays
Cells were seeded in a 96-well plate (8  103 HeLa cells or
1.2  104 C-33A cells per well). Twenty-four hours later, the cells
medium was replaced with fresh medium containing ﬁve different
concentrations of FBS (0%, 1%, 3%, 6% and 10%) for cell survival as-
says or six different concentrations of cisplatin (0, 0.04, 0.2, 1, 5
and 25 lg/ml) for cytotoxicity assays. The cells were then incu-
bated at 37 C for another 24 or 48 h and cell viability was deter-
mined by MTT assays. The absorbance at 570 nm (A570) of each
well was read on a spectrophotometer. The inhibition rate (IR) of
each group was calculated by the formula: IR = ((XY)/X)  100%.
X is the A570 of the untreated group and Y is the A570 of each group
with cisplatin treatment. The concentration at which each drug
produced 50% inhibition of growth (IC50) was estimated using
the IR. Three independent experiments were performed in
triplicate.Table 1
Primers used in the construction of plasmids and qRT-PCR.
Usage Primer name Sequence (50–
Construction for Bcl2l2 EGFP reporters Bcl2l2-UTR-S 50-GAGTAAGC
Bcl2l2-UTR-MA 50-CCAACTTT
Bcl2l2-UTR-MS 50-CATTAAGG
Bcl2l2-UTR-AS 50-CAGTCGCT
qRT-PCR for miR-214 miR-214 RT 50-GTCGTATC
miR-214 Forward 50-TGCGGACA
Reverse primer 50-CCAGTGCA
qRT-PCR for U6 snRNA U6 RT 50-GTCGTATC
U6 Forward 50-TGCGGGTG
Reverse primer 50-CCAGTGCA
Construction for pSilencer2.1-U6 neo/Bcl2l2 shBcl2l2-Top 50-GATCCCGC
shBcl2l2-Bot 50-AGCTTTTC
Construction for pcDNA3HA/Bcl2l2 Bcl2l2-PS 50-CAGGAATT
Bcl2l2-PA 50-GCCCTGCT
qRT-PCR for b-actin b-Actin-S 50-CGTGACAT
b-Actin-AS 50-CTAGAAGC
qRT-PCR for pri-miR-214 pri-miR-214-S 50-CATAGGAT
pri-miR-214-AS 50-GGGCGGA
qRT-PCR for Plexin-B1 Plexin-B1-S 50-CGCGGATC
Plexin-B1-AS 50-CGCGAATT
qRT-PCR for MEK3 MEK3-S 50-CGCGGATC
MEK3-AS 50-CGGAATTC
qRT-PCR for JNK1 JNK1-S 50-CGCGGATC
JNK1-AS 50-CGGAATTC2.3. TUNEL assays
HeLa/miR-214 and HeLa/Neg-Ctrl cells (4  103 cells/well) were
seeded on a 14-well slide (Cel-Line/Erie Scientiﬁc Co., NH, USA) in
triplicate. Twenty-four hours later, the medium was replaced with
fresh medium containing 0% FBS or 10% FBS for another 48 h.
Apoptosis was detected using an In situ Cell Death Detection Kit
with Fluorescein (Roche Applied Science, IN, USA). DNA was
stained with DAPI (Sigma–Aldrich, St Louis, MO, USA). The TUNEL
assays were quantiﬁed by counting the DAPI and TUNEL-positive
cells in ﬁve individual ﬁelds via ﬂuorescence microscopy respec-
tively. The apoptotic rate was calculated by dividing the average
number of TUNEL-positive cells by that of the DAPI-positive cells
in one ﬁeld. The assays were repeated three times.
2.4. RNA extraction and qRT-PCR
Total RNA was isolated using Trizol (Invitrogen, Carlsbad, CA,
USA) according to the manufacturer’s instructions. QRT-PCR was
performed as previously described to assess the expression level
of miR-214, primary transcript of miR-214 (pri-miR-214) and the
mRNA levels of Bcl2l2, JNK1, MEK3 and Plexin-B1 using the 2DDCT
method [6]. U6 snRNA or b-actin mRNA was used as internal stan-
dards to normalize the expression of miR-214 or the expression of
pri-miR-214 and other mRNAs, respectively. The speciﬁc primer
pairs were shown in Table 1.
2.5. Plasmids construction
According to the known functional siRNA sequence [8], the se-
quences, shBcl2l2-Top and shBcl2l2-Bot, were annealed and in-
serted into the BamHI and HindIII sites of pSilencer2.1-U6 neo
(Ambion, Austin, USA) vector to generate a shRNA expression plas-
mid against Bcl2l2, pSilencer2.1-U6 neo/Bcl2l2 (sh-Bcl2l2). PSi-
lencer2.1-U6 neo negative control (sh-Neg-Ctrl, Ambion, Austin,
USA) was used as a negative control plasmid.30)
GGCCGCGGCTGGGCAATTTGCCCTCA-30
TTTTCTCGTGCAAACCCCTTAATG-30
GGTTTGCACGAGAAAAAAAGTTGG-30
CGAGCTCCTCTTGGCTAAAGGTCC-30
CAGTGCAGGGTCCGAGGTGCACTGGATACGACACTGCCTG-30
GCAGGCACAGAC-30
GGGTCCGAGGT-30
CAGTGCAGGGTCCGAGGTGCACTGGATACGACAAAATATGG-30
CTCGCTTCGGCAGC-30
GGGTCCGAGGT-30
TCGGTCCTGCGATTATTATTCAAGAGATAATAATCGCAGGACCGAGTTTTTTGGAAA-30
CAAAAAACTCGGTCCTGCGATTATTATCTCTTGAATAATAATCGCAGGACCGAGCGG-30
CGCCACCATGGCGACCCCAGCCTCGGCCCCAG-30
CGAGGCCTTGCTAGCAAAAAAGGCCCCTAC-30
TAAGGAGAAGCTG-30
ATTTGCGGTGGAC-30
CCAGATCTGCTGAACTCTGACTACATG-30
ATTCTATTTCATAGGCACCACTC-30
CCCTGGTGAAGCCAAGTGAT-30
CTGGTGTCCTGGTCGGAGAT-30
CAAAGAAGCAGACC-30
AAAGCCGGGATAGAGG-30
CAAAGATCCCTGACAAG-30
CTAACCGACTCCCCATC-30
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quence was ampliﬁed by PCR using Bcl2l2-PS and Bcl2l2-PA from
the cDNA of HeLa cells and cloned into the pcDNA3HA plasmid
(constructed by our laboratory), which allows the expression of a
hemagglutinin (HA) tag at the c-terminal of the protein of interest
using the EcoRI and XhoI sites. The resulting plasmid was desig-
nated as pcDNA3HA/Bcl2l2. All of the constructs were conﬁrmed
by DNA sequencing. The primers were provided in Table 1.
2.6. Western blot analysis
Total cellular extracts were extracted using RIPA buffer. Proteins
were separated by 12% SDS–PAGE, and proteins of interest were de-
tected using the appropriate antibodies. Rabbit anti-humanGAPDH,
tubulin, HA, caspase-8, caspase-9 and caspase-3 antibodies were
fromSaierbio (Tianjin,China).Rabbit anti-humanBcl2l2andBaxpri-
mary antibodies were obtained from Abcam (Cambridge, UK) and
Santa Cruz Biotechnology (CA, USA), respectively.
2.7. Target prediction and EGFP reporter assays
Based on bioinformatic prediction (PicTar, miRanda and Target-
Scan), Bcl2l2 was selected from anti-apoptotic subset as candidate
target ofmiR-214. The 30UTR segments of Bcl2l2 containing putative
binding sites for miR-214 were obtained by PCR and inserted into
pcDNA3/EGFP (constructed previously [9]). The wild-type reporter
construct pcDNA3/EGFP-Bcl2l2-UTR and the mutant reporter con-
struct pcDNA3/EGFP-Bcl2l2-UTRmut, in which the site of perfect
complementarity to miR-214 was mutated (CTGCTG? CACGAG)
using site-directed mutagenesis PCR, were used for miRNA func-
tional analysis. Wild-type and mutant insertions were conﬁrmed
by DNA sequencing. All primer information is available in Table 1.
For EGFP reporter experiments, HeLa cells were co-transfected
with the wild-type or mutant 30UTR EGFP construct and the miR-
214 expression vector pcDNA3/miR-214 (constructed previously
[6]) or pcDNA3 negative control vector. The vector pDsRed2-N1
(Clontech, USA) expressing RFP was used for normalization. EGFP
and RFP levels were measured at 48 h after transfection as previ-
ously described [9]. Each experiment was repeated at least three
times.
2.8. Treatment of cells with 5-aza-20-deoxycytidine and Trichostatin A
HeLa cells were seeded into 60-mm dishes on day 0 and ex-
posed to the DNA methyltransferase inhibitor 5-aza-CdR (5-aza-Fig. 1. Ectopic expression of miR-214 in HeLa cells signiﬁcantly reduces cell survival
cultured with various concentrations of FBS for 24 h or 48 h and subjected to cell surviv
seeded into 96-well plate. Twenty-four hours later, the medium was replaced with cispl
and cell inhibition rates were calculated. The bars represent means ± S.D. of three indepdeoxycytidine; Sigma–Aldrich; 5 lM) from day 1 to day 4. Mean-
while, the histone deacetylase inhibitor TSA (trichostatin A; Sig-
ma–Aldrich; 0.1 lM) was added to the cells on day 3. Cells
treated with 5-aza-CdR, TSA, or both were harvested on day 4.
The mock-treated group received a comparable treatment with
ethanol. QRT-PCR was used to examine the expression of pri-
miR-214, miR-214 and Bcl2l2. Known target genes of miR-214,
including Plexin-B1, MEK3 and JNK1, were used as positive con-
trols. All the primers used are shown in Table 1.
2.9. Statistical analysis
Statistical signiﬁcance between groups was assessed using AN-
OVA or Student’s t-test. The data are presented as means ± S.D.
Pearson’s correlation was employed to analyze the relationship be-
tween two factors. P < 0.05 was considered to be statistically
signiﬁcant.3. Results
3.1. Over-expression of miR-214 reduces cell survival and enhances
cisplatin-induced cytotoxicity in HeLa cells
In order to investigate the role of miR-214 in survival and sen-
sitivity to cisplatin, cell survival assays and cytotoxicity assays
were performed using HeLa/miR-214 and HeLa/Neg-Ctrl cells. We
found that the viability of HeLa/miR-214 was signiﬁcantly lower
than that of HeLa/Neg-Ctrl cells in all serum conditions (Fig. 1A),
and HeLa/miR-214 cells required only half as much cisplatin to
achieve the same level of cell death as the HeLa/Neg-Ctrl cells at
48 h (Fig. 1B).
3.2. Bcl2l2 is a direct target of miR-214
To explore the mechanisms through which miR-214 inhibits
cell survival and increases cellular sensitivity to cisplatin, we
searched for potential targets of miR-214 using bioinformatic algo-
rithms. One predicted miR-214-binding site (2690–2711 nt) was
found within the 30UTR of Bcl2l2 mRNA (Fig. 2A). Then we con-
structed EGFP reporter plasmids carrying the wild-type or mutant
30UTR sequence (shown in Fig. 2A) and performed the EGFP repor-
ter assays. As shown in Fig. 2B, the normalized intensity of ﬂuores-
cence was signiﬁcantly reduced in the pcDNA3/miR-214- and wild-
type EGFP reporter plasmid-transfected group as compared to theand resistance to cisplatin. (A and B) HeLa/miR-214 and HeLa/Neg-Ctrl cells were
al assays detected by MTT assays. (B) HeLa/miR-214 and HeLa/Neg-Ctrl cells were
atin-containing medium for another 48 h. Cell viability was assessed by MTT assays
endent experiments. ⁄P < 0.05, ⁄⁄P < 0.01.
Fig. 2. Bcl2l2 is a direct target gene of miR-214. (A) A sequence alignment of miR-214 with wild-type Bcl2l2 mRNA is shown. The arrows indicate the mutant nucleotides. (B)
HeLa cells were co-transfected with either wild-type or mutant Bcl2l2 30UTR EGFP construct and pcDNA3/miR-214 for 48 h, along with the pDsRed2-N1 for normalization.
The vector pcDNA3 was used as a negative control. The graph depicts averaged results from three experiments. Data represent means ± S.D. (C and D) HeLa/miR-214 and
HeLa/Neg-Ctrl cells were harvested to analyze the endogenous expression of Bcl2l2 mRNA (C) and protein (D) using qRT-PCR and western blot analysis, respectively. b-actin
or GAPDH was used as endogenous control for Bcl2l2 mRNA or protein expression, respectively. (E and F) The relative expressions of miR-214 (E) and Bcl2l2 mRNA (F) in
cervical cancerous tissues compared to adjacent normal cervical tissues were determined by qRT-PCR. U6 snRNA or b-actin was used for miR-214 or Bcl2l2 mRNA
normalization respectively. (G) Pearson’s correlation was used to analyze the relationship between the expression of miR-214 and Bcl2l2 mRNA in 11 paired cervical tissues.
⁄P < 0.05, ⁄⁄P < 0.01, P > 0.05.
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tween the pcDNA/miR-214 and the pcDNA3 group when the mu-
tant EGFP reporter plasmid was transfected (Fig. 2B). These
results demonstrate that miR-214 can bind directly to the Bcl2l2
30UTR to repress gene expression.
We went onto measure the endogenous expression of Bcl2l2 in
HeLa cells with various levels of miR-214. As shown in Fig. 2C and
D, Bcl2l2 mRNA and protein levels were both inhibited in HeLa/
miR-214 cells, indicating miR-214 can negatively regulate the
expression of Bcl2l2 at the post-transcriptional level. Consistent
with previous studies [6,10], we also observed an obvious decrease
in the expression of miR-214 and a signiﬁcant increase in the
expression of Bcl2l2 mRNA in cervical cancerous tissues relative
to non-cancerous cervical tissues (Fig. 2E and F) which was inver-
sely correlated (R = 0.826) (Fig. 2G).
3.3. Knockdown of Bcl2l2 in HeLa cells leads to decreased cell survival
and increased cisplatin-induced cytotoxicity
We also transfected a shRNA expression vector targeted against
Bcl2l2 (sh-Bcl2l2) into HeLa cells after the validity was conﬁrmed
(Fig. 3A) and tested cell survival and sensitivity to cisplatin. Asshown in Fig. 3B and C, knockdown of Bcl2l2 in HeLa cells obvi-
ously decreased cellular viability in various conditions and in-
creased the sensitivity to cisplatin by 8-fold. The respective
IC50 doses for cisplatin were 0.32 lg/ml (HeLa cells transfected
with sh-Bcl2l2) and 2.4 lg/ml (HeLa cells transfected with sh-
Neg-Ctrl).
3.4. Restoration of Bcl2l2 expression in HeLa/miR-214 cells reverses the
changes in cell survival and resistance to cisplatin induced by miR-214
If the effect of excess miR-214 is speciﬁc, co-expression of
Bcl2l2 protein should be able to suppress the miR-214 over-
expression phenotype. The plasmid expressing Bcl2l2 pcDNA3-
HA/Bcl2l2, which signiﬁcantly increased the protein expression of
Bcl2l2 (Fig. 4A) was transfected into HeLa/miR-214 cells followed
by cell survival and cytotoxicity assays. As shown in Fig. 4B and
C, pcDNA3HA/Bcl2l2 signiﬁcantly increases cell viability under all
serum conditions and cisplatin-resistance in HeLa/miR-214 cells
compared to the pcDNA3HA-transfected group. To achieve the
same level of cell death, HeLa/miR-214 cells with high levels of
Bcl2l2 (IC50, 13.59 lg/ml) required 4.85 times the concentration
of cisplatin compared to control cells (IC50, 2.80 lg/ml).
Fig. 3. Knockdown of Bcl2l2 signiﬁcantly inhibits cellular survival and resistance to cisplatin in HeLa cells. HeLa cells were transfected with sh-Bcl2l2 or sh-Neg-Ctrl. (A) At
48 h after transfection, cells were collected and the lysates were subjected to western blot analysis with an anti-Bcl2l2 antibody. GAPDH was used as an internal control. (B
and C) Cell survival assays and cytotoxicity assays were performed at 24 h after transfection. ⁄⁄P < 0.01.
Fig. 4. Restoration of Bcl2l2 counteracts the effects of ectopic expression of miR-214. HeLa/miR-214 cells were transfected with pcDNA3HA/Bcl2l2 or pcDNA3HA. (A) At 48 h
after transfection, cells were collected and the lysates subjected to western blot analysis with an anti-HA antibody. GAPDH was used as an internal control. (B and C) Cell
survival assays and cytotoxicity assays were performed at 24 h after transfection. ⁄⁄P < 0.01.
Fig. 5. miR-214-reduced cell survival and resistance to cisplatin can be contracted by re-expression of Bcl2l2 in C-33A cells. C-33A cells (1  106 cells/well) were seeded into
60-mm dishes and co-transfected with pcDNA3/miR-214 (2.5 lg each well) and pcDNA3HA/Bcl2l2 or pcDNA3 (1.5 lg each well), with pcDNA3 (4 lg per well) as negative
control. (A) The expression of Bcl2l2 was examined by western blot analysis at 48 h post-transfection. (B and C) Cell survival and cytotoxicity assays were also performed at
24 h after transfection. ⁄⁄P < 0.01.
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and resistance to cisplatin in another cervical cancer C-33A cells,
which was counteracted by re-expression of Bcl2l2
We went on investigating whether miR-214 exert the similar
function on cell survival and cisplatin-induced cytotoxicity
through targeting Bcl2l2. As expected, in C-33A cells, ectopic
expression of miR-214 signiﬁcantly inhibited Bcl2l2 expression
(Fig. 5A), reduced cell survival (Fig. 5B) and induced sensitivity to
cisplatin (Fig. 5C). And pcDNA3HA/Bcl2l2 was also able to restore
the decreased cell viability and cisplatin-resistance in C-33A cells
(Fig. 5B and C).3.6. Over-expression of miR-214 promotes apoptosis via caspase-8 and
-9 activation
We further investigated whether miR-214 could alter the sensi-
tivity of HeLa cells to apoptosis upon serum deprivation using
TUNEL assays. As shown in Fig. 6A, HeLa/Neg-Ctrl cells showed al-
most no green ﬂuorescence regardless of the amount of serum,
whereas HeLa/miR-214 cells showed weak or strong ﬂuorescence
when incubated with 10% FBS or 0% FBS (Fig. 6A). In addition, en-
hanced expression of Bax (21 KDa), caspase-9 (47 KDa), caspase-3
(33 KDa), caspase-8 (57 KDa) was found in Hela/miR-214 cells
compared with HeLa/Neg-Ctrl cells, in parallel with the elevated
Fig. 6. Ectopic expression of miR-214 induces apoptosis in HeLa cells, especially under serum-depleted conditions. (A) HeLa/miR-214 and HeLa/Neg-Ctrl cells were treated
with or without serum and detected by TUNEL assays. Representative photos (original magniﬁcation  200) and apoptosis rate were shown. (B) HeLa/miR-214 and HeLa/Neg-
Ctrl cells incubated with or without serum for 48 h were harvested. The expression of Bax, caspase-9, caspase-3 and caspase-8 were analyzed by western blot analysis.
GAPDH or tubulin was used as a loading control. The relative expressions were shown. (C) HeLa cells were transfected with pcDNA3HA/Bcl2l2 or pcDNA3HA, along with
pcDNA3/miR-214. 24 h later, cells were treated with 0% FBS for another 48 h. Then the expressions of the above proteins were also detected by western blot with GAPDH as
control. The relative expressions were shown. ⁄P < 0.05, ⁄⁄P < 0.01, P > 0.05.
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and caspase-8 (18 KDa), and the strongest expressions of these
apoptosis-related proteins were occurred in HeLa/miR-214 cells
under conditions of serum deprivation (Fig. 6B). Moreover, restora-
tion of Bcl2l2 in HeLa cells transfected with pcDNA3/miR-214 abol-
ished the increased expression of all of the above apoptosis-related
protein except caspase-8 (the expression of active caspase-8 was
not detected, Fig. 6C), Together, these data demonstrate that ecto-
pic expression of miR-214 induces apoptosis through activation of
caspase-9 and caspase-8 in HeLa cells upon serum deprivation,
which was partly related with Bcl2l2 inhibition.
3.7. DNA demethylation and histone acetylation decrease pri-miR-214
expression, whereas increase miR-214 expression in HeLa cells
It is well known that epigenetic mechanisms, including DNA
methylation and histone acetylation, regulate miRNA expression
[11–12]. Here we found that the expression of pri-miR-214 was
down-regulated, whereas the mature miR-214 was up-regulatedupon treatment with 5-aza-CdR and/or TSA (Fig. 7A and B). Fur-
thermore, the most pronounced inhibition of pri-miR-214 and
the most signiﬁcant increase of miR-214 are both present in HeLa
cells treated with 5-aza-CdR and TSA simultaneously (Fig. 7A and
B). In addition, the expression of Bcl2l2 and other known direct
miR-214 target genes, including MEK3, JNK1 and Plexin-B1 [5–6],
decreased signiﬁcantly in HeLa cells treated with 5-aza-CdR and/
or TSA compared with mock treated controls (Fig. 7C).
4. Discussion
MiR-214 has been found to be aberrantly expressed in human
tumors and to play various roles in cancer development. Previous
studies have shown that miR-214 is up-regulated and functions
as an oncogene in human ovarian cancer and pancreatic cancer,
in which miR-214 can promote cell survival and resistance to cis-
platin or gemcitabine [13–14]. However, our previous reports have
showed that miR-214 is down-regulated in cervical cancer tissues
and suppresses cell proliferation, migration and invasion in cervi-
Fig. 7. MiR-214 is regulated in HeLa cells by DNA methylation and histone deacetylation. HeLa cells were treated with 5-aza-CdR and/or TSA and the expression levels of pri-
miR-214 (A), mature miR-214 (B) and its target genes, including Bcl2l2, MEK3, JNK1 and Plexin-B1 (C), were measured by qRT-PCR, with b-actin as internal controls for pri-
miR-214 and target genes or U6 snRNA for mature miR-214. Ctrl, mock treated group. Data represent means ± S.D. ⁄⁄P < 0.01, versus control group.
494 F. Wang et al. / FEBS Letters 587 (2013) 488–495cal cancer cells by targeting MEK3, JNK1, Plexin-B1 and GALNT7,
thus functioning as a tumor suppressor [5–7]. Here, we showed
that miR-214 can reduce cell survival, promote apoptosis and in-
duce sensitivity to cisplatin in HeLa and C-33A cells, supporting
the tumor suppressor role of miR-214 in cervical cancer.
Identiﬁcation and characterization of the targets of altered miR-
NAs may help elucidate the molecular mechanisms involved in car-
cinogenesis. Bcl2l2, also known as Bcl-w, which is a member of the
Bcl-2 protein family, has been reported to promote cell survival
[15], reduce apoptosis in response to apoptotic stimuli [16], and
contribute to chemoresistance [17]. It has also been found to be
over-expressed in non-small cell lung cancer [18], gastric and co-
lon cancers [19–20] and result in their carcinogenesis. In the pres-
ent study, we found that Bcl2l2 was up-regulated in cervical cancer
tissues and promoted cell survival and resistance to cisplatin,
which conﬁrmed the previous reports. Furthermore, we showed
that miR-214 reduced the mRNA and protein expression of Bcl2l2
at post-transcriptional level through directly binding the 30UTR of
Bcl2l2. The inverse correlation between miR-214 levels and Bcl2l2
mRNA levels in cervical cancer tissues supported this conclusion.
Moreover, we veriﬁed that enforced expression of Bcl2l2 counter-
acted the effects of miR-214 on cell survival and resistance to cis-
platin in HeLa cells. Together, these data suggest that Bcl2l2 is
indeed a direct target gene of miR-214.
We went onto detail the apoptosis-related mechanisms in-
volved in miR-214’s action. Apoptosis induced by serum starvation
is generally accepted to be caspase dependent. Caspase-3 activity isessential for apoptosis after serum withdrawal [21], but whether
apoptosis occurs via the extrinsic pathway (characterized by cas-
pase-8 activation) or the intrinsic pathway (characterized by cas-
pase-9 activation) remains controversial. Here we found that
ectopic expression of miR-214 in HeLa cells increased the expres-
sions of Bax, caspase-9, caspase-8 and caspase-3, which were
partly reversed by over-expression of Bcl2l2. These data indicate
that not only the extrinsic pathway but also the intrinsic pathway
is involved in the apoptosis induced by enforced expression of
miR-214. Moreover, the increased expression of Bax and decreased
expression of Bcl2l2 observed in response to high levels of miR-214
may contribute to a pronounced increase in the Bax/Bcl2l2 ratio
and the increase in apoptosis. Together, our data provide the evi-
dence that miR-214 may induce apoptotic signals at least in part
through regulation of the amount of Bcl2l2. However, how miR-
214 increases the expression of Bax is still unclear.
Moreover, we showed epigenetic regulation by DNA methyla-
tion and histone deacetylation may be responsible for the down-
regulation of miR-214 observed in HeLa cells. But the inconsistence
between the pri-miR-214 and miR-214 expression level upon epi-
genetic regulation is hard to explain. Fortunately, the enhanced
expression of mature miR-214 via 5-aza-CdR and TSA treatment
was also veriﬁed in another report by Yamane et al., which support
our results [22]. Other than that, they found the down-regulation
of miR-214 in squamous cell carcinoma cell line most likely caused
by hypermethylation of other promoter regions rather than the
miR-214 promoter, which may be one reason for the inhibited
F. Wang et al. / FEBS Letters 587 (2013) 488–495 495transcription of miR-214 upon 5-aza-CdR treatment [22]. In addi-
tion, Twist-1, the important transcriptional activator of miR-214
[23], has been reported to be remarkably suppressed by seven
reactivated miRNAs with hypermethylation in their upstream
CpG islands in human ductal carcinomas [24] and high level of
miR-214 in intrahepatic cholangiocarcinoma [25]. Thus, the
down-regulation of Twist-1 upon demethylation or enhanced
miR-214 may lead to the transcriptional inhibition of pri-miR-
214. Moreover, histone deacetylase 1 has been shown to enhance
miRNA processing via deacetylation of DGCR8 [26]. Therefore,
the regulation of pri-miR-214 and miR-214 are too sophisticated
to elucidate simply by one or two reasons. The detail mechanism
of miR-214 transcription and processing in HeLa cells deserves fur-
ther investigation.
In summary, we here report that miR-214 expression signiﬁ-
cantly reduces cell survival and enhances cisplatin-induced cyto-
toxicity, increasing HeLa cell apoptosis (especially under
conditions of serum depletion and cytotoxic agent treatment). Be-
cause decreases in apoptosis are critical in cancer development and
constitute a major barrier to effective treatment, miR-214 may
serve as a novel therapeutic target in cervical cancer.
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